Literature DB >> 18081882

Medication with antihistamines impairs allergen-specific immunotherapy in mice.

P Johansen1, G Senti, J Maria Martínez Gómez, T M Kündig.   

Abstract

BACKGROUND: Histamine released from activated mast cells and basophils is an important mediator in allergy. Therefore, antihistamines are efficiently and widely used to suppress allergic symptoms.
OBJECTIVE: This study evaluated the role of antihistamines in sensitization against allergens and in the efficiency of allergen-specific immunotherapy.
METHODS: CBA mice were sensitized and de-sensitized with bee venom allergen extracts and the major allergen phospholipase A2. Clemastine was used to test the effect of a histamine-1 receptor antagonist on the immune responses to phospholipase A2.
RESULTS: The results demonstrated that sensitization against bee venom was strongly enhanced during treatment with antihistamines. Clemastine increased IgE production while decreasing IgG2a production against bee venom. This T-helper type 2 shift of the humoral response appeared to be caused by reduced IFN-gamma and enhanced IL-4 secretion from allergen-specific T cells. We also found reduced TNF-alpha, IL-6 and major histocompatibility complex class-II expression by macrophages. In sensitized mice, the efficiency of allergen-specific immunotherapy was reduced by clemastine treatment.
CONCLUSION: Antihistamines may enhance allergic sensitization and reduce the efficiency of allergen-specific immunotherapy. Future studies will need to demonstrate to what extent pre-medication with antihistamine also affects allergen-specific immunotherapy in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081882     DOI: 10.1111/j.1365-2222.2007.02904.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  5 in total

Review 1.  [Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy].

Authors:  B Wedi; F Ruëff
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

2.  Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Joseph R Podojil; Mahesh V Padval; Stephen D Miller
Journal:  Cell Immunol       Date:  2011-05-31       Impact factor: 4.868

3.  Prophylactic and Therapeutic Potential of Asp f1 Epitopes in Naïve and Sensitized BALB/c Mice.

Authors:  Neelkamal Chaudhary; Lakshna Mahajan; Taruna Madan; Anil Kumar; Gajendra Pratap Singh Raghava; Seturam Bandacharya Katti; Wahajul Haq; Puranam Usha Sarma
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

4.  Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance.

Authors:  Alice Köhli-Wiesner; Lisbeth Stahlberger; Christian Bieli; Tamar Stricker; Roger Lauener
Journal:  J Allergy (Cairo)       Date:  2011-07-19

5.  Murine subcutaneous immunotherapy models with beneficial immunological and physiological effects.

Authors:  Yoon-Seok Chang; Yoon-Keun Kim; Sae-Hoon Kim; Heung-Woo Park; Kyung-Up Min; You-Young Kim; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2013-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.